Keyphrases
COVID-19
100%
Randomized Placebo-controlled Trial
66%
Metformin
66%
SARS-CoV-2 Infection
38%
Viral Load
38%
Antiviral Activity
38%
Sequencer
33%
Illumina Sequencing
33%
Size Bias
33%
Highly Accurate
33%
Graft-versus-host Disease (GvHD)
33%
Microbial Signatures
33%
Intestinal Acute Graft-versus-host Disease
33%
Stress Response
33%
M2 Macrophages
33%
Recount
33%
Seroprevalence
33%
Health Inequities
33%
COVID-19 Vaccination
33%
Steroid-refractory Acute Graft-versus-host Disease
26%
Steroid-refractory
26%
Placebo
22%
Disease Onset
20%
Transmission Mitigation
20%
Mitigation Behaviour
20%
Plasmid
16%
Hospitalization
16%
Coronavirus Disease (COVID)
16%
High-level Expression
13%
Programmed Death-ligand 1 (PD-L1)
13%
Indoleamine 2,3-dioxygenase 1 (IDO1)
13%
TIGIT
13%
Amphiregulin
13%
T Cells
13%
Aryl Hydrocarbon Receptor
13%
Expression Level
13%
Gene Expression Profile
13%
Black Americans
13%
Native American
13%
Hispanic
13%
SARS-CoV-2 Seroprevalence
13%
African American or Black
13%
Alaskan Native
13%
Protein Translation
12%
Fluvoxamine
11%
Ivermectin
11%
Confidence Interval
10%
SARS-CoV-2 Viral Load
9%
DNA Quantification
8%
Counting Method
8%
Medicine and Dentistry
Severe Acute Respiratory Syndrome Coronavirus 2
100%
COVID-19
80%
Controlled Clinical Trial
66%
Glycon
66%
Placebo
66%
Infection
38%
Seroprevalence
33%
COVID-19 Vaccination
33%
Antivirus Agent
33%
Translation (Protein Synthesis)
12%
Fluvoxamine
11%
Ivermectin
11%
Outpatient
11%
Antiviral Therapy
9%
Prevalence
9%
Virus RNA
8%
Antiviral Activity
8%
Postcovid Syndrome
8%
Odds Ratio
6%
Pharmacology, Toxicology and Pharmaceutical Science
SARS Coronavirus
100%
Controlled Clinical Trial
66%
Metformin
66%
Placebo
66%
Infection
38%
Antivirus Agent
38%
Seroprevalence
33%
Diseases
33%
Coronavirinae
33%
Ivermectin
11%
Fluvoxamine
11%
Prevalence
9%
Virus RNA
8%
Antiviral Activity
8%
